Clinical Trials Browser

INDUSTRY × Recurrence × pembrolizumab × Clear all

NCT06984328 2026-06-02

Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

Phase 2 Active not recruiting

Melanoma, Recurrence

NCT05533697 2026-05-28

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

Neoplasm Metastasis, Neoplasms, Recurrence

NCT06880549 2026-05-27

A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors

Phase 1 Active not recruiting

Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence

NCT04534205 2026-05-22

AHEAD-MERIT

Phase 2/3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

NCT05537740 2026-05-20

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

BreastDermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Recurrence, Triple Negative Breast Neoplasms

NCT05359445 2026-04-30

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

Phase 1 Active not recruiting

Neoplasms, Recurrence

NCT05047094 2026-04-06

Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC

Phase NA Recruiting

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Recurrence, Skin Neoplasms

NCT04220866 2025-10-29

MK-1454-002

Phase 2 Completed

18 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT02628574 2025-08-03

Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab

Phase 1 Completed

Neoplasm Metastasis, Recurrence

NCT04815720 2025-01-08

KEYNOTE-B84

Phase 1/2 Completed

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Neoplasm Metastasis, Recurrence

NCT06016920 2024-12-17

Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma

Phase 1/2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT03340766 2024-10-17

HARBOUR

Phase 1 Completed

31 enrolled 29 charts

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04478695 2024-03-08

Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Terminated

1 enrolled 2 charts

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT05357898 2024-02-23

Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence

NCT03941262 2023-11-13

Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy

Phase 1 Completed

Neoplasm Metastasis, Neoplasms, Recurrence

NCT03168438 2022-01-11

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

Phase 1 Terminated

6 enrolled 19 charts

Multiple Myeloma, Neoplasms, Recurrence

NCT03144245 2021-10-12

Study of AMV564 in Patients With AML

Phase 1 Completed

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute